Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy
Journal of Medical Imaging and Radiation Oncology · 2026
DOI: 10.1111/1754-9485.70066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2026. Verfasst von Philip Macilwraith und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Melanoma, Immune Checkpoint Inhibitors, Immunotherapy. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Aim
To evaluate the incidence of pseudoprogression on 18 F‐FDG PET/CT scans in metastatic melanoma patients commencing immune checkpoint inhibitor therapy and to determine the average time to confirmed 18 F‐FDG PET/CT response in the pseudoprogression cohort identified.
Methods
Patients with metastatic melanoma who underwent baseline and follow‐up 18 F‐FDG PET/CT scans after commencing immune checkpoint inhibitor therapy at Alfred Hospital (2012–2023) were retrospectively reviewed. Cases of pseudoprogression were identified by a keyword search of reports and confirmed on image review by a nuclear medicine physician. Data on timing of confirmed response, immune‐related adverse events, and autoimmune history were also collected.
Results
10/401 (2.49%) metastatic melanoma patients were confirmed as having pseudoprogression on PET/CT. 8/10 (80%) had new FDG‐avid lesions and 2/10 (20%) had an increase in size and SUVmax of original disease. 8/10 (80%) of patients achieved complete metabolic remission on subsequent PET/CT scans with an average time to confirmed reduction of disease on PET/CT of 28.4 weeks. 4/10 (40%) received dual agent immunotherapy. 8/10 (80%) developed irAEs of varying types and severity. 2/10 (20%) had a history of pre‐existing autoimmune disease. 9/10 (90%) of pseudoprogression patients are alive at last review.
Conclusion
Pseudoprogression on 18 F‐FDG PET/CT occurred in approximately 2.5% of metastatic melanoma patients commencing immunotherapy with an average time to subsequent confirmed response of ~6 months. This highlights the importance of not ceasing immunotherapy prematurely based on early 18 F‐FDG PET/CT findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia.
- Monash University, Melbourne, Victoria, Australia.
- Department of Nuclear Medicine and PET, Alfred Hospital, Melbourne, Victoria, Australia.
- Department of Dermatology, Alfred Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: Philip Macilwraith, Mark Shackleton, Andrew Haydon, David Nadebaum, Victoria Mar, Vivek Naranbhai
Zitieren
APA
Macilwraith, P., Shackleton, M., Haydon, A., Nadebaum, D., Mar, V., Naranbhai, V., & Cherk, M. H. (2026). Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.70066
Vancouver
Macilwraith P, Shackleton M, Haydon A, Nadebaum D, Mar V, Naranbhai V, et al. Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy. Journal of Medical Imaging and Radiation Oncology. 2026. doi:10.1111/1754-9485.70066
BibTeX
@article{Macilwraith2026,
author = {Macilwraith, Philip and Shackleton, Mark and Haydon, Andrew and Nadebaum, David and Mar, Victoria and Naranbhai, Vivek and Cherk, Martin H},
title = {Incidence of Reported Pseudoprogression on 18 F ‐ FDG PET / CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2026},
doi = {10.1111/1754-9485.70066}
}
EUVIMED